Today’s AI Top Pick: TASK

8/4/2026 · Low Float Bullish Consensus Deep Rotation screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Measured daily model accuracy · TASK86%337 resolved forecasts · 45d window · verify →

Today's pick · Low Float Bullish Consensus Deep RotationTASKBUY NOW8.0 / 108/4/2026

TaskUs (TASK) is the cleanest intersection of cheap fundamentals, multi-timeframe forecast agreement, and supportive news on this list. Valuation is genuinely attractive for a profitable name: fwdPe 4.13, PE 5.6, ROE 26.52%, profitMargin 8.7%, salesYoY +15.95%, with an analyst recom of 1 (strong buy consensus on the screen) and targetUpsidePct 38.4%. Unlike most of the pool (which is unprofitable micro-cap biotech), TASK actually earns money, and it still trades like a broken growth name after a -42.7% year and -17.2% YTD — that's the setup you want when the tape turns.

Entry zone

$6.00–$6.25 (current $6.21; ideal add on any dip toward the 4h VWAP)

Stop loss

$5.55 (below the 4h -3.88% drawdown pivot and 1h swing low)

First target

$6.90 (aligns with 4h fc_short +47% blend and pos-in-range top)

Longer target

$8.00–$8.75 (captures 1d fc_mid +31.4% and 1wk fc_long +27.83%, roughly analyst target)

Risks

1h fc_short is -9.71% and pos_in_21bar_range is 78.84% — near-term extended, so a 3–5% pullback is very plausible before continuation
recom is 2.86 (only mildly positive) despite bullish_prob 1 — sell-side is not uniformly on board yet
debtEq 1.99 is elevated; a rate/credit shock would compress the fwdPe 4.13 discount
Top-client concentration risk was flagged by Wedbush (they said exit is unlikely, but the fact it's discussed = latent overhang)
shortFloat 11.31% — squeeze fuel on the way up, but also crowded fade if 1wk recent_21bar -8.21% resumes

Honorable mentions

AZOBest pure fundamentals in the pool (fwdPe 17.06, recom 1.42, instOwn 93.89%, targetUpside 32.5%, positive undervaluation write-up 8/3), 1d fc_mid +20.29% and 4h fc_mid +11.03% with position only 31.9% of 4h range — but 1wk fc_mid/long are -5.99%/-5.35%, so multi-timeframe agreement isn't perfect. Great BUY_NOW for size, just not as tight a setup as TASK.

GPIfwdPe 6.44, peg 0.78, profitable auto retailer sitting at 0% of range on 4h/1d/1wk with all three timeframes forecasting +14% to +34%. The only reason it's not #1: JP Morgan just downgraded (8/1), which caps near-term upside and explains why it's pinned at the range low. Better as BUY_PULLBACK once the downgrade digests.

Full ranking (30)

#	Symbol	Verdict	Score	Read
1	TASK	BUY NOW	8.0	fwdPe 4.13 + profitable + 4h/1d/1wk fc all positive (+47%/+31%/+28%) + Wedbush positive — best fundamentals-meets-tape combo.
2	AZO	BUY NOW	7.2	Blue-chip screen winner (recom 1.42, instOwn 93.9%) with 1d fc +20.3% and low 1h range position 6.7%; weekly fc slightly negative is the only knock.
3	GPI	BUY PULLBACK	6.7	Deep-value auto retailer at 0% of 4h/1d/1wk range with +14–34% forecasts, but JPM downgrade 8/1 caps immediate upside.
4	LBRDA	BUY PULLBACK	6.4	All four TFs bullish (1d fc +49%, 1wk fc +90%) and Comcast spin-off tailwind, but 1d position 93.4% = chasing risk.
5	MORN	WAIT	5.6	Great fundamentals (roe 31.96, peg 0.77) but RSI 68.65, pos-in-range 98.6–100% and 1h/4h fc -19.4%/-10.8% — post-earnings extension, wait for pullback.
6	GRCE	BUY PULLBACK	5.4	FDA Type A meeting positive (7/28), 1d fc +58% mid, position 0–2% of range — oversold biotech with a real catalyst.
7	BCDA	BUY PULLBACK	5.2	FDA regulatory path supported (6/5), 1wk fc_long +240%, but at 6–30% of range with heavy drawdown; needs base.
8	XTLB	BUY PULLBACK	5.0	All TFs bullish (1wk fc +117%) and near-term_bullish 0.8, but $6.8M cap = illiquid, no fundamentals to anchor.
9	IDN	WAIT	4.9	Profitable (profitMargin 9.56, roe 11.38) with peg-friendly valuation but 1wk fc negative and 1h fc +154% looks like a single-bar outlier.
10	EVGN	WAIT	4.8	1d fc +90% and PCSK9 pipeline news, but salesYoY -72.7% and $8M cap — narrative play only.
11	QNTM	WAIT	4.6	1wk fc +663% is an outlier; recent_21bar +37.95% weekly means late chase, roe -984%.
12	LTRN	BUY PULLBACK	4.5	Open-Medicine AI spin-out (8/3) + EMA clearance are real catalysts, but 1h/4h fc mixed and 1wk fc -55% flags dilution risk.
13	TNXP	WAIT	4.4	FDA Type C meeting (8/3) is positive, but only 2 TFs available and 1wk fc +36,132% is a data outlier — untradeable signal.
14	CNCK	WAIT	4.3	Crypto-adjacent narrative + Bhutan treasury mandate, but 1h fc -24% and 56M share resale prospectus 7/31 = overhang.
15	NXL	WAIT	4.2	1d fc_long +94% and Brazil trial positive, but ps 28.7, profitMargin -3022%, sub-$1 with 1wk position 4.4%.
16	NXTC	WAIT	4.1	Avere merger transforms thesis; short float 48.67% + all-stock deal makes this event-driven, not signal-driven.
17	YCBD	WAIT	4.0	New Mexcor distribution deal but 1d fc_short -9%, drawdowns 27% across TFs — no clean entry.
18	WW	WAIT	3.9	PE 0.15 optically cheap and 1d fc_long +43%, but debtEq 1.76 + only 1 TF available = insufficient confirmation.
19	PRSO	WAIT	3.8	1h fc +52% and 4h fc +32% look constructive, but Q1 missed revenue estimates and salesYoY -40.57%.
20	GLMD	WAIT	3.7	Aramchol Parkinson's/cardiac news is interesting narrative, but only 1h and 4h TFs available, $4.8M cap.
21	LUCY	WAIT	3.6	Claude AI integration + $3M warrant exercise (dilution), 1h drawdown -39.7%, only 3 TFs — too messy.
22	INDP	WAIT	3.5	1wk fc +692% but 4h at 0% range + -63% drawdown; falling knife with no news catalyst since 9/2025.
23	DARE	WAIT	3.3	debtEq 9.84, profitMargin -1038%, drawdowns 38–40% across TFs — screen pass but broken chart.
24	IPWR	AVOID	3.2	Filed $75M shelf on 7/10 = dilution overhang, ps 2118 nonsensical, 1d fc_short -1.46%.
25	RGNT	WAIT	3.1	Japan patent + EU approval are positives, but bullish_prob null, only 2 TFs, -49% drawdown on 1d.
26	INTZ	AVOID	2.9	1wk fc_short/mid/long all -55.37% and Zacks flagged it lagging market twice in past 2 weeks.
27	HCWB	AVOID	2.7	Priced $1.6M private placement at $2.58 on 7/29 = dilution; 1wk fc +931% is a broken-scale outlier, not signal.
28	USBC	AVOID	2.4	bullish_prob 0.2, near_term_bullish 0, 1d fc_short -45%, 1wk fc +1103% is nonsensical scaling — untradeable.
29	COSM	AVOID	2.2	1wk fc all -89.95% and $14M cap penny stock with roe -92%; the screen pass is misleading.
30	CRE	AVOID	2.0	bullish_prob null, no forecast tfs shown, perfYear -96%, no recom — broken.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord